Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

Pyrroline-5-caroxylate reductase, M. tuberculosis Recombinant

Catalyzes the reduction of 1-pyrroline-5-carboxylate (PCA) to L-proline
Catalog #: P1456
SKU-Size Size Price Qty
P1456-10 100 µg
P1456-50 50 µg
More Sizes Get Quote

Product Details

Alternate Name P5CR, PCA reductase, P5C reductase, proC
Gene Symbol proC
Gene ID 887256
Accession # P9WHU7
Source E. coli
Appearance Lyophilized powder
Physical Form Description Lyophilized
Molecular Weight 49.4 kDa with N-terminal TRX tag
Purity by SDS-PAGE ≥90%
Biological Activity This enzyme has a specific activity of ≥ 7 mU/mg based on its conversion of proline to pyrroline-5-caboxylate.
Reconstitution Instructions Reconstitute the lyophilized protein with 30% Glycerol and 5 mM BME at the concentration of 0.5 mg/ml. Incubate the reconstituted protein at 25 °C for 15 minutes.
Amino Acid Sequence 1 – 295
Handling Centrifuge the vial prior to opening.
Storage Conditions -20ºC
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


P5CR catalyzes the NADH dependent reaction of converting pyrroline-5-caboxylate to proline. It is important for regulating amino acid metabolism, intracellular redox potential, and apoptosis. Increased P5CR expression and activity have been observed in carcinoma and pulmonary tumors.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.